Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$80.52 USD
+0.72 (0.90%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $80.53 +0.01 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CORT 80.52 +0.72(0.90%)
Will CORT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CORT
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer
Can Korlym Drive Corcept's Growth Through the Rest of 2025?
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Other News for CORT
Is CORT gaining bullish strength? Expansion Breakout shows up after surging 6.15%
CORT forms Directional Movement Crossover Bullish on September 18
CORT Crossed Above 20 Day Moving Average on September 16
CORT Fell Below 20 Day Moving Average on September 15
CORT forms Bollinger Band Squeeze on September 12